EP
TRDA icon

Essential Partners’s Entrada Therapeutics TRDA Stock Holding History

Essential Partners’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.63K Sell
414
-183
-31% -$1.27K ﹤0.01% 1811
2026
Q2 		$4.39K Buy
597
+443
+288% +$4.25K ﹤0.01% 1605
2026
Q1 		$1.94K Buy
154
+103
+202% +$1.18K ﹤0.01% 2017
2025
Q4 		$524 Buy
51
+40
+364% +$337 ﹤0.01% 2221
2025
Q3 		$64 Buy
11
+6
+120% +$35 ﹤0.01% 2542
2025
Q2 		$34 Buy
+5
New +$40 ﹤0.01% 2184

Other funds holding TRDA

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Essential Partners's TRDA Position: Q3 2026 in Review

Essential Partners reduced its Entrada Therapeutics (TRDA) stake by 31% in Q3 2026, selling an estimated $1.27K and leaving 414 shares worth $2.63K. The position accounts for ﹤0.01% of the portfolio, ranked #1811.

Essential Partners first reported a position in TRDA in Q2 2025 and has held it in 6 quarters since. The position peaked at $4.39K in Q2 2026. 8 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.

  • Essential Partners held 414 shares of Entrada Therapeutics worth $2.63K as of Q3 2026.
  • Essential Partners sold 183 Entrada Therapeutics shares in Q3 2026, an estimated $1.27K.
  • Entrada Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1811 holding.
  • Essential Partners first reported a position in Entrada Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Entrada Therapeutics position peaked at $4.39K in Q2 2026.
  • 8 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.